Rich-Vicks' ibuprofen/pseudoephedrine "synergy" claim "irrelevant" to patent suit -- McNeil.
This article was originally published in The Tan Sheet
Executive Summary
RICH-VICKS' IBUPROFEN/PSEUDOEPHEDRINE "SYNERGY" CLAIM "IRRELEVANT," McNEIL maintained in a brief filed with the U.S. Court of Appeals for the Federal Circuit on May 22. The document responds to Richardson-Vicks' appeal of a Jan. 17 district court decision that the Procter & Gamble unit's patent for 200 mg ibuprofen/30 mg pseudoephedrine in cough/cold products was not valid and enforceable because the combination was obvious to anyone with medical experience in the OTC cough/cold industry ("The Tan Sheet" Jan. 22, p. 1).